株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

エピネフリン自己注射器の世界市場:2017年~2021年

Global Epinephrine Autoinjector Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 282669
出版日 ページ情報 英文 84 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.36円で換算しております。
Back to Top
エピネフリン自己注射器の世界市場:2017年~2021年 Global Epinephrine Autoinjector Market 2017-2021
出版日: 2017年02月17日 ページ情報: 英文 84 Pages
概要

エピネフリンは、アナフィラキシー症候群治療の第一選択肢となる医薬品であり、緊急事態時の救命薬となり得るとみなされています。エピネフリン自己注射器は1980年代にはすでに、重症のアレルギー患者の生命維持に役立つと実証されていました。1987年にEpiPenがFDA (米国食品医薬品局) に認証されて以来、技術開発が継続的に行われてきています。エピネフリン自己注射器の世界市場は、2017年から2021年にかけて、14.58%のCAGR (複合年間成長率) で拡大することが予測されています。

当レポートでは、世界のエピネフリン自己注射器市場について分析し、製品の概要や市場の基本構造、市場規模の動向 (今後5年間の予測値)、投与量別・年齢層別・エンドユーザー別・地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・推計しております。

第1章 エグゼクティブ・サマリー

第2章 分析範囲

  • 分析概要
  • 大手ベンダーの主要製品

第3章 市場分析の手法

  • 分析手法
  • 経済指標

第4章 イントロダクション

  • 市場動向の概略
  • エピネフリン自己注射器:概要

第5章 市場環境

  • 市場概要
  • 市場規模とその予測
  • ファイブフォース分析

第6章 投与量別の市場区分

  • 投与量0.15グラムの場合
  • 投与量0.30グラムの場合
  • 投与量0.5グラムの場合

第7章 年齢層別の市場区分

第8章 エンドユーザー別の市場区分

  • 病院・診療所
  • 個人

第9章 地域区分

  • 南北アメリカ市場
  • 欧州・中東・アフリカ諸国 (EMEA) 市場
  • アジア太平洋地域市場

第10章 市場促進要因

  • アレルギー有病者数の増加
  • 技術進歩
  • マーケティング戦略

第11章 促進要因の影響力

第12章 市場の課題

  • 製品リコールと規制上の課題
  • 代替的製品の存在
  • コストの高さ

第13章 促進要因・課題の影響力

第14章 市場の動向

  • 実験的製品の発売
  • エピネフリン自己注射器の認知度の上昇
  • 患者支援プログラム

第15章 ベンダー環境

  • 競争シナリオ
  • 近年の主な動向
  • 主要ベンダーの地域ごとのプレゼンス分析

第16章 主要ベンダーの分析

  • ALK-Abello
  • Impax Laboratories
  • Lincoln Medical
  • Mylan
  • その他の有力ベンダー

第17章 付録

  • 略語集

第18章 Technavioについて

図表一覧

図表
  • Exhibit 01: Product offerings
  • Exhibit 02: Global epinephrine autoinjector market: Analysis
  • Exhibit 03: Key buying criteria for epinephrine autoinjectors
  • Exhibit 04: Buying criteria for epinephrine autoinjectors
  • Exhibit 05: Key factors influencing development of epinephrine autoinjectors
  • Exhibit 06: Allergy statistics
  • Exhibit 07: Market overview: Global epinephrine autoinjector market
  • Exhibit 08: Global epinephrine autoinjector market ($ millions)
  • Exhibit 09: Global epinephrine autoinjector market analysis: Developed and developing markets
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Global epinephrine autoinjector market segmentation by dosage 2016
  • Exhibit 12: Global epinephrine autoinjector market segmentation by dosage 2020
  • Exhibit 13: Global epinephrine autoinjector market by 0.15gm dosage 2016-2021 ($ millions)
  • Exhibit 14: Global epinephrine autoinjector market by 0.30gm dosage 2016-2021 ($ millions)
  • Exhibit 15: Global epinephrine autoinjector market by 0.5gm dosage 2016-2021 ($ millions)
  • Exhibit 16: Global epinephrine autoinjector market segmentation by dosage 2016-2021 (%)
  • Exhibit 17: Global epinephrine autoinjector market segmentation by dosage 2016-2021 ($ millions)
  • Exhibit 18: Global epinephrine autoinjector market by age group 2016
  • Exhibit 19: Global epinephrine autoinjector market by end-user 2016
  • Exhibit 20: Global epinephrine autoinjector market segmentation by geography 2016
  • Exhibit 21: Global epinephrine autoinjector market segmentation by geography 2021
  • Exhibit 22: Epinephrine autoinjector market in the Americas 2016-2021 ($ millions)
  • Exhibit 23: Market overview: Americas
  • Exhibit 24: Epinephrine autoinjector market overview: US
  • Exhibit 25: Epinephrine autoinjector market in the US 2016-2021 ($ millions)
  • Exhibit 26: Market overview: EMEA
  • Exhibit 27: Epinephrine autoinjector market in EMEA 2016-2021 ($ millions)
  • Exhibit 28: Market overview: APAC
  • Exhibit 29: Epinephrine autoinjector market in APAC 2016-2021 ($ millions)
  • Exhibit 30: Global epinephrine autoinjector market segmentation by geography 2016-2021 ($ millions)
  • Exhibit 31: Global epinephrine autoinjector market segmentation by geography 2016-2021 (%)
  • Exhibit 32: Allergy statistics
  • Exhibit 33: Technological advances
  • Exhibit 34: Marketing strategies of Mylan
  • Exhibit 35: Impact of drivers
  • Exhibit 36: Product recalls
  • Exhibit 37: Alternatives of epinephrine autoinjectors in the market
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: Competitive structure of the global epinephrine autoinjector market
  • Exhibit 40: Market penetration of various epinephrine autoinjector manufacturers globally (2016)
  • Exhibit 41: Strategic success factors of companies in global epinephrine autoinjector market 2016
  • Exhibit 42: Share of vendors in global epinephrine autoinjector market 2016
  • Exhibit 43: Regional analysis of key vendors
  • Exhibit 44: Key highlights of ALK-AbellA³
  • Exhibit 45: ALK-AbellA³ strength assessment
  • Exhibit 46: ALK-AbellA³ strategy assessment
  • Exhibit 47: ALK-AbellA³ opportunity assessment
  • Exhibit 48: Key highlights of Impax Laboratories
  • Exhibit 49: Impax Laboratories strength assessment
  • Exhibit 50: Impax Laboratories strategy assessment
  • Exhibit 51: Impax Laboratories opportunity assessment
  • Exhibit 52: Lincoln Medical strength assessment
  • Exhibit 53: Lincoln Medical strategy assessment
  • Exhibit 54: Lincoln Medical opportunity assessment
  • Exhibit 55: Key highlights of Mylan
  • Exhibit 56: Mylan strength assessment
  • Exhibit 57: Mylan strategy assessment
  • Exhibit 58: Mylan opportunity assessment
目次
Product Code: IRTNTR12027

About epinephrine autoinjector

Epinephrine is among the first line of treatment drugs for anaphylactic conditions and is considered a life-saving drug during emergencies. Epinephrine autoinjectors have proved to be a life savior for people with severe allergies from as early as the 1980s. The global epinephrine autoinjector market has been witnessing continuous technological innovations and developments over the years, after the first FDA approval of EpiPen in 1987.

Technavio's analysts forecast the global epinephrine autoinjector market to grow at a CAGR of 14.58% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global epinephrine autoinjector market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of various epinephrine autoinjectors to key end-users such as hospitals, clinics, and individuals.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Epinephrine Autoinjector Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • ALK-Abello
  • Impax Laboratories
  • Lincoln Medical
  • Mylan

Other Prominent Vendors

  • Adamis Pharmaceuticals
  • Antares Pharma
  • Emerade
  • Hospira
  • Kaleo Pharma
  • Teva Pharmaceutical Industries

Market driver

  • Increasing prevalence of allergies
  • For a full, detailed list, view our report

Market challenge

  • Product recalls and regulatory issues
  • For a full, detailed list, view our report

Market trend

  • Tentative product launches
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Epinephrine autoinjector: Overview

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by dosage

  • Global epinephrine autoinjector market by 0.15gm dosage
  • Global epinephrine autoinjector market by 0.30gm dosage
  • Global epinephrine autoinjector market by 0.5gm dosage

PART 07: Market segmentation by age group

PART 08: Market segmentation by end-user

  • Hospitals and clinics
  • Individuals

PART 09: Geographical segmentation

  • Epinephrine autoinjector market in the Americas
  • Epinephrine autoinjector market in EMEA
  • Epinephrine autoinjector market in APAC

PART 10: Market drivers

  • Increasing prevalence of allergies
  • Technological advances
  • Marketing strategies

PART 11: Impact of drivers

PART 12: Market challenges

  • Product recalls and regulatory issues
  • Presence of substitutes
  • High cost

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Tentative product launches
  • Growing awareness about epinephrine autoinjectors
  • Patient assistance programs

PART 15: Vendor landscape

  • Competitive scenario
  • Key news
  • Geographical presence of key vendors

PART 16: Key vendor analysis

  • ALK-AbellA³
  • Impax Laboratories
  • Lincoln Medical
  • Mylan
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

Back to Top